This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CRISPR Therapeutics AG (CRSP) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.67%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $126.25 in the latest trading session, marking a -0.67% move from the prior day.
A Comprehensive Guide to Genomic ETFs
by Sweta Jaiswal, FRM
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
by Sweta Jaiswal, FRM
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals
Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data
by Zacks Equity Research
Intellia (NTLA) posts positive interim data from phase I study on lead genome-editing candidate NTLA-2001 being developed for treating transthyretin (ATTR) amyloidosis. Stock up.
3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data
by Zacks Equity Research
Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.
Stocks Roar Back on Infrastructure Expectations
by David Borun
The S&P 500 hits a fresh all-time high as Congress agrees to a bipartisan infrastructure bill.
Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study
by Zacks Equity Research
Editas (EDIT) starts enrollment of the first pediatric cohort in the phase I/II BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10). Stock up.
High-Growth Stocks Jump Back Into Investors' Favor
by Daniel Laboe
The short-term bottom for next-generation enterprises is in, and high multiple stocks are returning to investors' favor.
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.83, marking a +0.44% move from the previous day.
CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases
by Zacks Equity Research
CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.
CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.
It Was a Very Quiet Week for US Equities, but a Significant Fed Meeting Looms
by David Borun
Stocks have found an equilibrium level for a slow Summer, yet this week all eyes are on the Fed for clues about interest rates.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $114.74, moving -0.92% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Down 12.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stocks Wind Up Largely Unchanged as Cryptos Nosedive.
by David Borun
US equities suffer briefly but recover as the price of Bitcoin falls 50% from its peak.
Vertex (VRTX) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Vertex (VRTX) beats both earnings and sales estimates in Q1 and keeps product sales outlook for 2021.
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.
CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -4.14% and -89.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $126.55, marking a +0.52% move from the previous day.
Is a Beat in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.